English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/62920
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment

AuthorsGenebat, Miguel; Leal, Manuel; Pulido, Ildefonso; Romero-Sánchez, M.; González-Serna, Manuel Alejandro; Ferrando-Martínez, Sara; Machmach, K.; Pacheco, Yolanda M. ; Ruiz-Mateos, Ezequiel
Issue Date2012
PublisherElsevier
CitationAntiviral Research 95(3): 207-211 (2012)
AbstractThe maraviroc clinical test (MCT) is a clinical approach to establish the indication of maraviroc treatment. In this study, we analysed the long-term outcome of patients receiving a combined antiretroviral therapy (cART) selected according to MCT results. Ninety-two consecutive HIV-infected patients underwent MCT. A virological response (<40 HIV-RNA copies/ml after 24. weeks) was observed in 76/92 patients (82.6%). These patients (n= 76) were included in a time to treatment failure analysis; after a mean follow-up period of 88. weeks, treatment failure was confirmed in 14 patients (18.4%). Tropism switch during MCT was observed in 3/35 patients (8.6%); these patients experienced excellent long-term outcome on cART. In conclusion, MCT should be considered as an additional method before CCR5-antagonists prescription. © 2012 Elsevier B.V.
URIhttp://hdl.handle.net/10261/62920
DOI10.1016/j.antiviral.2012.06.007
Identifiersdoi: 10.1016/j.antiviral.2012.06.007
issn: 0166-3542
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.